Ganglioside GD2 as a marker and target on cancer stem cells
US9846160B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 27, 2013 |
| Grant date | Dec 19, 2017 |
| Priority date | — |
| Expiry date | Jan 6, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.